The three DOACs most widely used currently in the UK for the primary and secondary prevention of stroke in patients with non-valvular AF (the most common form of AF) are direct inhibitors of activated factor X (anti-FXa DOACs, namely apixaban, edoxaban and rivaroxaban) [5, 9–11]. The gene discussed is F10; the disease is atrial fibrillation.